

	<p align="center">Single Photon Emission Computed Tomography (SPECT) Scan Guidelines</p>	
<p align="center">Guideline # 6201</p>	<p align="center">Categories Clinical → Care Coordination, Care Coordination – Utilization management , TCHP Guidelines</p>	<p align="center">This Guideline Applies To: Texas Children's Health Plan</p>
		<p align="center">Document Owner Lisa Fuller</p>

GUIDELINE STATEMENT:

Texas Children's Health Plan (TCHP) performs authorization of all Single photon emission computed tomography (SPECT) scans.

DEFINITIONS:

Single photon emission computed tomography (SPECT): An imaging modality that provides three-dimensional images of the concentration of a radiopharmaceutical within various tissues and organs. Indications may include but are not limited to: evaluation of stress fractures, spondylosis, infection (e.g., discitis), tumor (e.g., osteoid osteoma), blood flow to an organ, (e.g. myocardial viability), or to differentiate ischemic heart disease from dilated cardiomyopathy.

PRIOR AUTHORIZATION GUIDELINES

1. All requests for prior authorization for SPECT scans are received via online submission, fax, phone or mail by the Utilization Management Department and processed during normal business hours.
2. The Utilization Management professional receiving the request evaluates the submitted information to determine if the documentation supports the SPECT scan request as an eligible service.
3. To request prior authorization for SPECT scan, the following documentation must be provided:
 - 3.1. Diagnosis
 - 3.2. Treatment history
 - 3.3. Treatment plan
 - 3.4. Medications that the member is currently taking
 - 3.5. Previous imaging results
 - 3.6. Signed physician order for the ordered test
4. SPECT scan is considered medically necessary in the following clinical scenarios:
 - 4.1. Cardiac

- 4.1.1. Diagnosis of coronary artery disease (CAD) with abnormal resting electrocardiogram (ECG) and restricted exercise intolerance
- 4.1.2. Assessment of prognosis in members with CAD with impediments or contraindications to non-nuclear stress testing according to American College of Cardiology (ACC) guidelines include **any** of the following:
 - A history of physical impairments that would preclude physically performing the exercise portion of a stress test
 - A history of prior proven ischemic cardiac events
 - Proven CAD by past SPECT or coronary catheterization
 - When ECG would prevent interpretation of a standard stress testing by being “uninterpretable” during the test, i.e., left bundle branch block (LBBB), paced rhythm, Wolf Parkinson White syndrome, left ventricular hypertrophy (LVH) with ST segment depression, or digoxin use
 - A history of congestive heart failure with history of re-vascularization. Repeat nuclear imaging as frequently as annually may be medically necessary
- 4.1.3. Assessment of myocardial viability before referral for revascularization

4.2. Non-Cardiac

- 4.2.1 Brain tumors: to differentiate between lymphomas and infections such as toxoplasmosis particularly in the immunosuppressed, or recurrent tumor vs. radiation changes, when PET is not available
- 4.2.2 Liver hemangioma: using labeled red blood cells to further define lesions identified by other imaging modalities
- 4.2.3 Localization of abscess/infection/inflammation in soft tissues or cases of fever of unknown origin
- 4.2.4 Neuroendocrine tumors (e.g., adenomas, carcinoid, pheochromocytomas, neuroblastoma, vasoactive intestinal peptide [VIP] secreting tumors, thyroid carcinoma, adrenal gland tumors): using a monoclonal antibody (OctreoScan™ [Covidien, Hazelwood, MO]) or I-131 meta-iodobenzyl-guanidine (MIBG)
- 4.2.5 Parathyroid imaging, including SPECT-CT fusion with laboratory evidence of hyperparathyroidism, enlarged parathyroid gland, and parathyroid hyperplasia or suspected parathyroid adenoma or carcinoma
- 4.2.6 Renal: Dimercaptosuccinic acid (DMSA) scan to assess the status of kidney for scarring and function
- 4.2.7 Diagnosing pulmonary embolism (by means of SPECT ventilation/perfusion scintigraphy)
- 4.2.8 Distinguishing Parkinson's disease from essential tremor
- 4.2.9 Lymphoma: to distinguish tumor from necrosis
- 4.2.10 Pre-surgical ictal detection of seizure focus in members with epilepsy (in place of positron emission tomography (PET))
- 4.2.11 Bone and joint conditions, to differentiate between infectious, neoplastic, avascular, or traumatic processes, including spondylolysis and stress fractures not visible from x-ray

5. SPECT scans are considered ***not medically necessary*** for the evaluation or management of cerebrovascular accident (CVA, stroke), subarachnoid hemorrhage, or transient ischemic attack.
6. SPECT is considered ***experimental/investigational and not medically necessary*** for all other non-cardiac indications, including ***any*** of the following, because its diagnostic value has not been established in the peer-reviewed medical literature in these situations.
 - 6.1. Diagnosis or assessment of members with attention deficit/hyperactivity disorder
 - 6.2. Diagnosis or assessment of members with autism
 - 6.3. Diagnosis or assessment of members with personality disorders (e.g., aggressive and violent behaviors, anti-social personality disorder including psychopathy, schizotypal personality disorder, as well as borderline personality disorder)
 - 6.4. Diagnosis or assessment of members with schizophrenia
 - 6.5. Diagnosis or assessment of stroke members
 - 6.6. Differential diagnosis of Parkinson's disease from other Parkinsonian syndromes
 - 6.7. Evaluation of members with endo leak
 - 6.8. Evaluation of members with generalized pain or insomnia
 - 6.9. Evaluation of members with head trauma
 - 6.10. Initial or differential diagnosis of members with suspected dementia (e.g., Alzheimer's disease, dementia with Lewy bodies, frontotemporal dementia, and vascular dementia)
 - 6.11. Multiple sclerosis
 - 6.12. Evaluation and diagnosis of members with Chronic Fatigue syndrome
 - 6.13. Colorectal carcinoma (e.g., used with the monoclonal antibody or IMMU-4 and CEA-Scan@[Immunomedics Inc., Morris Plains, New Jersey])
 - 6.14. Dopamine transporter (DaT) scan for all indications
 - 6.15. Malignancies other than those listed as medically necessary
 - 6.16. Neuropsychiatric disorders without evidence of cerebrovascular disease
 - 6.17. Pervasive development disorders (PDD)
 - 6.18. Prostate carcinoma (e.g., used with the monoclonal antibody ProstaScint® [EUSA Pharma, Langhorne, PA], with or without fusion imaging with computed tomography or magnetic resonance imaging)
 - 6.19. Scintimammography for breast cancer
 - 6.20. Pre-surgical evaluation of members undergoing lung volume reduction surgery
 - 6.21. Prosthetic graft infection
 - 6.22. Scanning of internal carotid artery during temporary balloon occlusion
 - 6.23. Vasculitis
 - 6.24. Detection of air leak/pneumothorax
 - 6.25. Evaluation of salivary gland dysfunction
 - 6.26. Diagnosis of painful legs and moving toes (PMLT) syndrome
 - 6.27. Evaluations of carotid stenosis
 - 6.28. As an imaging marker of pre-diagnostic Parkinson's disease
 - 6.29. Management of progressive supranuclear palsy
 - 6.30. Management of cortico-basal syndrome
 - 6.31. Surgical planning in individuals with axial neck and back pain from disc degeneration (spondylolysis)
 - 6.32. Malignancies other than those listed as medically necessary (Lung, ovarian cancers, differentiating between malignant and benign lung lesions)
 - 6.33. Any SPECT-CT fusion (other than parathyroid imaging)

- 6.34. SPECT/ultrasonography fusion imaging in persons with thyroid disease
- 6.35. Pre-surgical work up of individuals undergoing non-cardiac surgery

7. Cardiac exclusion criteria

7.1. SPECT is considered **experimental/investigational and not medically necessary** for the following indications for which the study is considered “inappropriate” according to appropriateness criteria from the American College of Cardiology (ACC):

- 7.1.1. As a routine screening evaluation after a percutaneous transluminal coronary angioplasty (PTCA) with or without stenting or coronary artery bypass surgery (CABG) prior to discharge from the acute care setting
- 7.1.2. As a routine screening evaluation after a re-vascularization procedure (PTCA with stenting or CABG) at an interval of less than 2 years from the procedure if there is no worsening in symptomatology and if the member had symptoms prior to the intervention, and there is no history of congestive heart failure
- 7.1.3. Assessment of vulnerable plaque
- 7.1.4. Evaluation of a member with an acute coronary event and hemodynamic instability, shock, or mechanical complications of the event
- 7.1.5. In the setting of acute chest pain or equivalent symptoms with a high likelihood of being acute coronary syndrome, when there has been a diagnosis of acute myocardial infarction, in the immediate post-thrombolytic period, or when there is a high pre-test likelihood of significant coronary disease as demonstrated by marked ST segment elevation on the ECG
- 7.1.6. Prior to high-risk* surgery when the member is asymptomatic and there was a normal cardiac catheterization, coronary intervention (PTCA, stenting, CABG), or normal nuclear stress test less than 1 year before the surgical date
- 7.1.7. Prior to intermediate-risk* non-cardiac surgery if the member is capable of, and has no contraindication to standard stress testing
- 7.1.8. Prior to low-risk* non-cardiac surgery for risk assessment
- 7.1.9. Re-evaluation of members without chest pain or equivalent symptoms, without known coronary disease, at high-risk for coronary disease (based upon the Framingham score greater than 10) who have an initial negative radionuclear imaging study, when it has been less than 2 years since the last radionuclear study
- 7.1.10. Re-evaluation of members without chest pain or equivalent symptoms or with stable symptoms, with known coronary disease as determined by prior abnormal catheterization or SPECT cardiac study (but without prior infarction), when it has been less than 1 year since the last radionuclear study. Note: if the member has worsening symptoms or if the member had silent ischemia, more frequent imaging or other diagnostic testing or interventions may be medically necessary
- 7.1.11. Screening of members with chest pain or chest pain equivalent symptoms when there is a low probability of coronary disease (Framingham score less than 10), no history of diabetes, and there are no impediments or contraindications to non-nuclear stress testing
- 7.1.12. Screening of members without chest pain or equivalent symptoms when there is a low probability of coronary disease (Framingham score less than 10) and no history of diabetes

7.2. Myocardial sympathetic innervation imaging, with or without SPECT is considered experimental and investigational as its effectiveness has not been established.

* Surgical Risk Categories

- **High-risk surgery** (risk of cardiac death or myocardial infarction (MI) greater than 5%): emergent major operations (particularly in the elderly), aortic and peripheral vascular surgery, prolonged surgical procedures associated with large fluid shifts and/or blood loss.
 - **Intermediate-risk surgery** (risk of cardiac death or MI 1% to 5%): carotid endarterectomy, head and neck surgery, surgery of the chest or abdomen, orthopedic surgery, prostate surgery.
 - **Low-risk surgery** (cardiac death or MI less than 1%): endoscopic procedures, superficial procedures, cataract surgery, breast surgery.
8. Requests that do not meet the criteria established by this procedure will be referred to a TCHP Medical Director/Physician Reviewer for review and the Denial Policy will be followed.
9. Preauthorization is based on medical necessity and not a guarantee of benefits or eligibility. Even if preauthorization is approved for treatment or a particular service, that authorization applies only to the medical necessity of treatment or service. All services are subject to benefit limitations and exclusions. Providers are subject to State and Federal Regulatory compliance and failure to comply may result in retrospective audit and potential financial recoupment.

REFERENCES:

Government Agency, Medical Society, and Other Publications:

Texas Medicaid Provider Procedure Manual, Accessed July 10, 2023.
<https://www.tmhp.com/resources/provider-manuals/tmppm>

Doherty, J. U., et al (2019). ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons. *Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography*, 32(5), 553–579.

Wolk, Michael J. et al. American College of Cardiology (Journal of the American College of Cardiology): 2013 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Stable Ischemic Heart Disease. *Journal ACC*. 2014; 63(4):380-406

Peer Reviewed Publications:

- Al-Oweidi AS, Albabtain H, Kharabsheh SM, et al. Prevalence and predictors of myocardial ischemia by preoperative myocardial perfusion single photon emission computed tomography in patients undergoing noncardiac surgery. *Ann Saudi Med.* 2017;37(6):461-468.
- Alster P, Madetko NK, Kozirowski DM, et al. Accumulation of tau protein, metabolism and perfusion-application and efficacy of positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging in the examination of progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). *Front Neurol.* 2019;10:101.
- Dorbala S, Ananthasubramaniam K, Armstrong IS, et al. Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging Guidelines: Instrumentation, Acquisition, Processing, and Interpretation. *Journal of Nuclear Cardiology.* 2018.
- Sirajuddin, A., Mirmomen, S. M., Kligerman, S. J., Groves, D. W., Burke, A. P., Kureshi, F., White, C. S., & Arai, A. E. (2021). Ischemic Heart Disease: Noninvasive Imaging Techniques and Findings. *Radiographics : a review publication of the Radiological Society of North America, Inc, 41(4)*, 990–1021.
- Packard, R. R. S., & Maddahi, J. (2019). Assessment of left ventricular mass by SPECT MPI. *Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 26(3)*, 906–908.
- Subramaniam RM, Frey KA, Hunt CH, et al. ACR–ACNM Practice Parameter for the Performance of Dopamine Transporter (DaT) Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders. *Clinical Nuclear Medicine.* 2017;42(11):847-852.
- Bega D, Gonzalez-Latapi P, Zadikoff C, et al. Is there a role for DAT-SPECT imaging in a specialty movement disorders practice? *Neurodegener Dis.* 2015;15(2):81-86.
- Brusko GD, Perez-Roman RJ, Tapamo H, et al. Preoperative SPECT imaging as a tool for surgical planning in patients with axial neck and back pain. *Neurosurg Focus.* 2019;47(6):E19.
- Ceulemans G, De Meirleir L, Keyaerts M, et al. Air leaks localized with lung ventilation SPECT. *Clin Nucl Med.* 2012;37(12):1182-1183.
- Ellis RJ, Kaminsky DA, Zhou EH, et al. Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (prostascint) in a cohort diagnosed with localized prostate cancer. *Int J Radiat Oncol Biol Phys.* 2011; 81(1):29-34.
- El-Zawahry AM, Clarke HS, Eskridge MR, et al. Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate. *Urology.* 2010; 76(5):1162-1167.
- Freesmeyer M, Opfermann T, Winkens T. Hybrid integration of real-time US and freehand SPECT: Proof of concept in patients with thyroid diseases. *Radiology.* 2014;271(3):856-861.

Joffe AR, Lequier L, Cave D. Specificity of radionuclide brain blood flow testing in brain death: case report and review. *J Intensive Care Med.* 2010; 25(1):53-64.

Kupsch AR, Bajaj N, Weiland F, et al. Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. *J Neurol Neurosurg Psychiatry.* 2012; 83(6):620-628.

Mohkam M, Maham S, Rahmani A, et al. Technetium Tc 99m dimercaptosuccinic acid renal scintigraphy in children with acute pyelonephritis: correlation with other imaging tests. *Iran J Kidney Dis.* 2010; 4(4):297-301.

Nishioka K, Suzuki M, Nakajima M, et al. Painful legs and moving toes syndrome evaluated through brain single photon emission computed tomography: A case series. *J Neurol.* 2019;266(3):717-725.

Noyce AJ, Dickson J, Rees RN, et al. Dopamine reuptake transporter-single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease. *Mov Disord.* 2018;33(3):478-482.

Bidesi, N. S. R., Vang Andersen, I., Windhorst, A. D., Shalgunov, V., & Herth, M. M. (2021). The role of neuroimaging in Parkinson's disease. *Journal of neurochemistry*, 159(4), 660–689.

Ozülker T, Ozülker F, Ozpaçacı T, et al. The efficacy of (99m)Tc-MIBI scintimammography in the evaluation of breast lesions and axillary involvement: a comparison with X-rays mammography, ultrasonography and magnetic resonance imaging. *Hell J Nucl Med.* 2010; 13(2):144-149.

Pan L, Han Y, Sun X, et al. FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis. *J Cancer Res Clin Oncol.* 2010; 136(7):1007-1022.

Pucar D, Sella T, Schöder H. The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. *Curr Opin Urol.* 2008; 18(1):87-97.

Sato Y, Matsumoto M. Clinical usefulness of multiphase arterial spin labeling imaging for evaluating cerebral hemodynamic status in a patient with symptomatic carotid stenosis by comparison with single-photon emission computed tomography: A case study. *Radiol Case Rep.* 2017;12(4):824-826.

Verschueren J, Huyghe I, Van den Wyngaert T. Ovarian cancer unmasked by technetium-99m bone scintigraphy and single-photon emission computed tomography-computed tomography. *World J Nucl Med.* 2019;18(1):58-60.

von Oertzen TJ, Mormann F, Urbach H, et al. Prospective use of subtraction ictal SPECT coregistered to MRI (SISCOM) in presurgical evaluation of epilepsy. *Epilepsia.* 2011; 52(12):2239-2248.

Weigert JM, Bertrand ML, Lanzkowsky L, et al. Results of a multicenter patient registry to determine the clinical impact of breast-specific gamma imaging, a molecular breast imaging technique. AJR Am J Roentgenol. 2012; 198(1):W69-W75.

Zhang S, Liu Y. Diagnostic performances of 99mTc-methoxy isobutyl isonitrile scan in predicting the malignancy of lung lesions: A meta-analysis. Medicine (Baltimore). 2016;95(18):e3571.

Zhou M, Johnson N, Gruner S, et al. Clinical utility of breast-specific gamma imaging for evaluating disease extent in the newly diagnosed breast cancer patient. Am J Surg. 2009; 197(2):159-163.

Status	Date	Action
Approved	08/18/2023	Clinical & Administrative Advisory Committee Reviewed and Approved for Implementation

Original Document Creation Date: 10/21/2016	This Version Creation Date: 08/19/2023	Effective/Publication Date: 08/31/2023
---	--	--